Loading
A target and a way of hitting it: ATP-competitive, allosteric or covalent kinase inhibitors, PARP trapping, hormone receptor blockade. The grid asks which targets have been hit with which mechanism class. The corpus holds 374 small-molecule inhibitors medicines: 201 approved, 89 in phase 3, 553 trials recruiting, 186 companies named. Every section below says which records it was read from.
From 1 record:Small-molecule kinase inhibitors
Pills that block the specific enzyme a cancer relies on. Imatinib in 2001 proved a cancer could be switched off by design.
ATP-competitive or allosteric binding to the kinase domain blocks phosphotransfer.
TermsOncogene addictionDrug resistance (primary and acquired)Synthetic lethality
From 374 records:AbemaciclibAbexinostatAbiraterone acetateABSK061ABT-301AcalabrutinibAcitretinAdagrasiband 366 more in the JSON
Target against mechanism class, 114 by 17. Open the grid, where every cell links to its medicines and the records behind its state.
From 201 records:Hydroxyurea (hydroxycarbamide)TamoxifenBromocriptineAminoglutethimideIsotretinoinDronabinolNabiloneSomatostatin analogues (octreotide, lanreotide)and 193 more in the JSON
From 89 records:AbexinostatAL2846AL8326ASC40AtebimetinibAtirmociclibAvasopasem manganeseAzenosertiband 81 more in the JSON
From 374 records:AbemaciclibAbexinostatAbiraterone acetateABSK061ABT-301AcalabrutinibAcitretinAdagrasiband 366 more in the JSON
And 104 more, every one a filter pill on the engine table.
And 7 more, every one a filter pill on the engine table.
From 186 records:NovartisPfizer (incl. Seagen)AstraZenecaMerck & Co. (MSD)Roche / GenentechEli Lilly (incl. Loxo)Bristol Myers SquibbTakedaand 178 more in the JSON
| Company | Type | Medicines | Approved | Phase 3 | Which |
|---|---|---|---|---|---|
| Novartis CH | pharma | 27 | 22 | 2 | |
| Pfizer (incl. Seagen) US | pharma | 23 | 19 | 3 | |
| AstraZeneca GB | pharma | 20 | 12 | 2 | |
| Merck & Co. (MSD) US | pharma | 12 | 7 | 5 | |
| Roche / Genentech CH | pharma | 11 | 7 | 4 | |
| Eli Lilly (incl. Loxo) US | pharma | 10 | 6 | 3 | |
| Bristol Myers Squibb US | pharma | 9 | 7 | 1 | |
| Takeda JP | pharma | 9 | 6 | 1 | |
| Johnson & Johnson US | pharma | 8 | 6 | 2 | |
| Sino Biopharmaceutical (Chia Tai Tianqing) CN | pharma | 7 | 1 | 4 | |
| Bayer DE | pharma | 6 | 6 | 0 | |
| Jiangsu Hengrui Pharmaceuticals CN | pharma | 6 | 4 | 2 | |
| Sanofi FR | pharma | 6 | 4 | 1 | |
| Hutchmed CN | biotech | 6 | 3 | 3 | |
| Ipsen FR | pharma | 5 | 5 | 0 | |
| Amgen US | pharma | 5 | 4 | 0 | |
| AbbVie (incl. ImmunoGen, Capstan) US | pharma | 5 | 3 | 1 | |
| Incyte US | biotech | 5 | 2 | 2 | |
| Merck KGaA (EMD Serono) DE | pharma | 4 | 4 | 0 | |
| Betta Pharmaceuticals CN | biotech | 4 | 3 | 0 |
The 166 others are in the JSON; every medicine's page names its companies.
From 553 records:(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal TumorsA Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCLand 545 more in the JSON
From 13 records:EnasidenibGilteritinibIvosidenibOlutasidenibZiftomenibEltrombopagFostamatinibRomiplostimand 5 more in the JSON
When a targeted drug makes leukaemia cells mature all at once, causing fever, fluid in the lungs, and weight gain. Treatable with steroids if caught early.
Linked fromEnasidenibGilteritinibIvosidenibOlutasidenibZiftomenib
Too few platelets, the blood cells that form clots, caused by chemotherapy or by the cancer in the marrow. Mild cases cause bruising; severe cases (under 10-20 × 10⁹/L) risk serious bleeding and need platelet transfusio…
Linked fromEltrombopagFostamatinibRomiplostim
High blood sugar as a side effect of drugs that block the PI3K/AKT pathway, because the same pathway carries insulin's signal in muscle and liver. It is the main reason these otherwise effective breast cancer drugs are…
Linked fromAlpelisibEverolimus
Eye problems from cancer drugs: blurred vision and corneal damage from certain ADCs (belantamab, tisotumab), retinal fluid from MEK inhibitors, and inflammation from immunotherapy. Usually reversible with dose holds, bu…
Linked fromBinimetinibErdafitinib
When a treatment kills cancer cells faster than the body can clear their contents, flooding the blood with potassium, phosphate and uric acid and injuring the kidneys and heart. Risk is highest in bulky CLL and high-cou…
Linked fromSonrotoclax
From 15 records:OsimertinibAmivantamabLorlatinibPalbociclibRibociclibAbemaciclibElacestrantVepdegestrantand 7 more in the JSON
Lung cancers on osimertinib escape by mutating the drug's binding site, switching on a bypass receptor (MET), or changing cell type entirely.
ExemplarsOsimertinibAmivantamab
Each ALK drug generation was beaten by a new mutation in the kinase; lorlatinib covers nearly all of them, so resistance now runs through other pathways.
ExemplarsLorlatinib
Hormone-positive breast cancer escapes either by mutating the oestrogen receptor so it no longer needs oestrogen, or by rewiring the cell-cycle engine (RB loss, cyclin E) so CDK4/6 no longer matters.
ExemplarsPalbociclibRibociclibAbemaciclibElacestrantVepdegestrant
Tumours that lost BRCA can regain repair by re-mutating BRCA back into working order, or by finding another way to protect their DNA.
ExemplarsOlaparibNiraparibTalazoparib
Blocking one RAS mutant makes the cell turn up every upstream receptor and often mutate KRAS again; that is why responses are short and why combinations and pan-RAS drugs followed.
Prostate cancer keeps the androgen receptor working without hormones (amplification, splice variants), or abandons it and becomes a neuroendocrine cancer.
ExemplarsCapivasertibLutetium-177 vipivotide tetraxetanOlaparib
From 394 records:Small-molecule kinase inhibitorsPARP inhibitorsCDK4/6 inhibitorsKRAS & RAS inhibitorsBCL-2 inhibitorsIDH inhibitorsMenin inhibitorsEndocrine therapy (SERMs, AIs, SERDs)and 386 more in the JSON
ADAURA: exploratory eight-year overall survival update for adjuvant osimertinib in resected EGFR-mutated stage IB to IIIA lung cancer Eight years after surgery, about three in four patients who took osimertinib for three years were still alive, compared with under six in t… | 2,026 | Journal of Thoracic Oncology | rct | |
Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial In 747 people whose advanced clear-cell kidney cancer had grown after immunotherapy, belzutifan plus lenvatinib kept the cancer from progre… | 2,026 | The Lancet | rct | |
Cancer therapy using antiparasitic medications guided by acupuncture meridian assessment: a case series of six patients Six patients with advanced cancers treated over a decade with antiparasitic drugs chosen by measuring electrical conductance at acupuncture… | 2,026 | Integrative Medicine (Encinitas) | observational | |
Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial The 812-patient trial in which adding the AKT inhibitor capivasertib to first-line paclitaxel did not lengthen life in metastatic triple-ne… | 2,026 | Annals of Oncology | rct | |
FLAURA2: long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced lung cancer Side effects of the osimertinib plus chemotherapy combination were most frequent in the first four chemotherapy cycles and fell steadily on… | 2,026 | Lung Cancer | rct | |
Ivermectin-benzimidazole prescribing following celebrity endorsement After a January 2025 podcast promoted ivermectin with a dog dewormer as a cancer cure, US prescriptions of the combination doubled overall… | 2,026 | JAMA Network Open | observational | |
KRYSTAL-12 plain language summary: adagrasib for non-small-cell lung cancer with KRAS G12C mutations A plain-language account of the KRYSTAL-12 trial, written for patients and carers, explaining how adagrasib compared with docetaxel chemoth… | 2,026 | Future Oncology | review | |
Real-world clinical outcomes of ivermectin and mebendazole in cancer patients: results from a prospective observational cohort (with 2026 expression of concern) A telemedicine company's survey of patients it prescribed ivermectin and mebendazole reported that most felt better; the journal has attach… | 2,026 | Anticancer Research | observational | |
Setmelanotide for the treatment of acquired hypothalamic obesity (TRANSCEND) In children and adults whose severe weight gain followed damage to the hypothalamus, a year of daily setmelanotide injections cut body-mass… | 2,026 | New England Journal of Medicine | rct | |
Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial The six-year OlympiA update: the year of olaparib still cut relapse by 35 percent and death by 28 percent, six-year survival was 87.5 versu… | 2,026 | Annals of Oncology | rct | |
AMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patients In AMPLIFY, an all-oral, 14-month course of acalabrutinib plus venetoclax beat FCR or BR chemo-immunotherapy in fit CLL patients, offering… | 2,025 | New England Journal of Medicine | rct | |
Avasopasem manganese treatment for severe oral mucositis from chemoradiotherapy for locally advanced head and neck cancer: phase 3 randomized controlled trial (ROMAN) Giving avasopasem before each radiotherapy session lowered the share of head and neck cancer patients who got severe mouth ulcers from 64 t… | 2,025 | eClinicalMedicine | rct | |
Beamion LUNG-1: zongertinib in previously treated HER2-mutant non-small-cell lung cancer The oral HER2-selective kinase inhibitor zongertinib shrank tumours in about seven in ten patients with previously treated HER2-mutant lung… | 2,025 | New England Journal of Medicine | observational | |
BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer Adding a BRAF inhibitor and an EGFR antibody to first-line chemotherapy roughly doubled survival in BRAF V600E-mutated metastatic bowel can… | 2,025 | New England Journal of Medicine | rct | |
CABINET (Alliance A021602): cabozantinib for advanced neuroendocrine tumours Cabozantinib delayed progression in previously treated advanced neuroendocrine tumours of both pancreatic and extra-pancreatic origin compa… | 2,025 | New England Journal of Medicine | rct | |
CEPHEUS: daratumumab quadruplet for newly diagnosed myeloma patients not having a transplant, with MRD-negativity as the main endpoint In patients who were transplant-ineligible or deferred transplant, the daratumumab quadruplet raised deep-remission rates from about 39% to… | 2,025 | Nature Medicine | rct | |
CLL12: ibrutinib in early-stage chronic lymphocytic leukaemia, a randomised placebo-controlled phase 3 trial Giving the pill ibrutinib to people with early, symptom-free chronic lymphocytic leukaemia delayed the disease but, after almost six years,… | 2,025 | Journal of Clinical Oncology | rct | |
LEAP-012: transarterial chemoembolisation with lenvatinib plus pembrolizumab versus placebo for unresectable non-metastatic hepatocellular carcinoma Adding lenvatinib and pembrolizumab to chemoembolisation delayed progression in intermediate-stage liver cancer, the second trial to show t… | 2,025 | The Lancet | rct | |
The threat of medical misinformation: a case of ivermectin toxicity in a pediatric oncology patient A letter describing severe ivermectin poisoning in a young patient with bone cancer who was also taking regorafenib, a cancer drug that sha… | 2,025 | Pediatric Blood & Cancer | observational | |
DUO-E: durvalumab with carboplatin-paclitaxel and maintenance durvalumab with or without olaparib in advanced endometrial cancer Adding durvalumab to first-line chemotherapy delayed progression in advanced endometrial cancer, and adding the PARP inhibitor olaparib to… | 2,024 | Journal of Clinical Oncology | rct | |
Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study Paper cited by one treatment page, indexed on Europe PMC as PubMed record 39127176 and published in Journal of Thoracic Oncology; the citin… | 2,024 | Journal of Thoracic Oncology | observational | |
FIRSTMAPPP: sunitinib for metastatic progressive phaeochromocytomas and paragangliomas In the first randomised trial in these rare tumours, sunitinib kept 36 percent of patients free of progression at one year against 19 perce… | 2,024 | The Lancet | rct | |
FIRSTMAPPP: sunitinib for metastatic progressive pheochromocytomas and paragangliomas The first randomised trial ever completed in metastatic pheochromocytoma and paraganglioma found that the kinase inhibitor sunitinib roughl… | 2,024 | The Lancet | rct | |
Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology guideline The 2024 American guideline says every woman diagnosed with breast cancer at 65 or under should be offered BRCA1/2 testing, as should anyon… | 2,024 | Journal of Clinical Oncology | guideline | |
IMerge: imetelstat, a telomerase inhibitor, for transfusion-dependent lower-risk MDS after erythropoietin has failed In IMerge, imetelstat, the first telomerase inhibitor to reach approval, freed about 40% of heavily transfused MDS patients from transfusio… | 2,024 | The Lancet | rct | |
INTUITT-NF2: brigatinib in NF2-related schwannomatosis with progressive tumours In people with the inherited condition NF2 whose nerve and brain-lining tumours were growing despite earlier treatment, the kinase inhibito… | 2,024 | New England Journal of Medicine | observational | |
MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer Combining an EGFR-MET bispecific antibody with a third-generation EGFR pill beat osimertinib alone, delaying progression by about seven mon… | 2,024 | New England Journal of Medicine | rct | |
MORPHO: gilteritinib as post-transplant maintenance for FLT3-ITD acute myeloid leukaemia Two years of the FLT3 blocker gilteritinib after a stem-cell transplant did not significantly reduce relapses across all patients, but it c… | 2,024 | Journal of Clinical Oncology | rct | |
NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer Three years of the CDK4/6 inhibitor ribociclib added to hormone therapy reduced relapses in stage II-III hormone-receptor-positive breast c… | 2,024 | New England Journal of Medicine | rct | |
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma Paper cited by one treatment page, indexed on Europe PMC as PubMed record 38335473 and published in Journal of Clinical Oncology; the citin… | 2,024 | Journal of Clinical Oncology | observational |
From 13 records:Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriersChemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugsctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatmentDrug discovery roadmap: screening in mice → maps of dependency → designing in silicoEpigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenomeHormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood testKRAS roadmap: undruggable → G12C → pan-RASPaediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children firstand 5 more in the JSON
From 394 records:Small-molecule kinase inhibitorsPARP inhibitorsCDK4/6 inhibitorsKRAS & RAS inhibitorsBCL-2 inhibitorsIDH inhibitorsMenin inhibitorsEndocrine therapy (SERMs, AIs, SERDs)and 386 more in the JSON
Molecular-class-directed adjuvant therapy in endometrial cancer Give adjuvant treatment by the tumour's molecular class rather than by stage and grade: nothing for POLE-mutated, immunotherapy for MMRd, chemotherapy plus tar… | Being tested at scale | |
MRD-guided treatment duration in CLL Instead of a fixed 12 or 15 months, stop each patient's therapy when their blood shows no detectable leukaemia, and restart if it returns. | Being tested at scale | |
Pool purchasing of essential cancer medicines across countries Small countries pay more for the same generic chemotherapy because they buy alone; the PAHO Strategic Fund and the WHO essential medicines list show that buyin… | Being tested at scale | |
Pooled international procurement of essential adult cancer medicines Countries buying cancer drugs alone pay more and face shortages. Buying together, as they already do for childhood cancer drugs and vaccines, cuts prices and s… | Being tested at scale | |
Prescribe a quarter dose of abiraterone with breakfast Taking 250 mg of abiraterone with a low-fat breakfast gives the same PSA response and testosterone suppression as the standard 1,000 mg fasting, because food i… | Being tested at scale | |
Publicly funded dose-reduction trials of expensive approved drugs Some expensive approved cancer drugs probably work as well at lower doses, as reduced-dose abiraterone with food and extended-interval checkpoint inhibitors su… | Being tested at scale | |
Publicly funded trials of lower and less frequent doses of expensive cancer drugs Abiraterone at a quarter dose with food matches full-dose exposure, and pembrolizumab and nivolumab can be given at longer intervals, but no manufacturer will… | Being tested at scale | |
Randomise at least two doses in phase 2 before any pivotal trial Cancer drugs are usually tested at the highest dose patients can stand, and that dose sticks for life. Comparing two or more doses head-to-head before the big… | Being tested at scale | |
Transparent cost-plus pricing for every oral oncology generic Generic imatinib and abiraterone can cost patients hundreds of dollars a month through insurance yet be sold at cost plus a fixed markup by transparent pharmac… | Being tested at scale | |
Transplant-free Ph-positive ALL for MRD-negative adults If a pill plus immunotherapy makes the leukaemia undetectable, can most adults safely skip a bone-marrow transplant? | Being tested at scale | |
A clone report from blood at every treatment cycle Blood tests can already detect tumour DNA. Reporting which sub-populations of the tumour are growing or shrinking, cycle by cycle, would turn the test into an… | Early clinical | |
A DRUP-style protocol for off-label generic targeted drugs in rare tumours Cheap generic versions of targeted cancer drugs like imatinib exist, but patients with rare tumours carrying the matching mutation often cannot get them. A str… | Early clinical | |
Add the second drug on day one when the escape route is predictable If most tumours escape a drug by the same back-up route, blocking that route from the start may prevent resistance rather than chase it. | Early clinical | |
Analyse and dose by sex: women get more toxicity from many cancer drugs at the same dose Women get more severe side effects than men at identical doses of fluorouracil, several kinase inhibitors and immune checkpoint inhibitors in pooled analyses.… | Early clinical | |
Autonomous closed-loop adaptive therapy driven by blood tests and evolutionary models Rather than giving the same dose until the cancer grows, measure tumour DNA in blood every few weeks and let a validated algorithm raise, lower, pause or switc… | Early clinical | |
Biomarker-selected adjuvant therapy in RCC (ctDNA, CAIX PET, gene signatures) Adjuvant immunotherapy after kidney cancer surgery is given to everyone at high pathological risk although most would never relapse, so a year of toxicity is s… | Early clinical | |
Block the recycling that keeps dormant cells alive Sleeping cancer cells survive by recycling their own contents. An old malaria drug blocks that recycling and is being tested in people with no visible cancer b… | Early clinical | |
BRAF/MEK plus PD-1 blockade as standard for BRAF-mutant anaplastic thyroid cancer Add immunotherapy to the two targeted pills in the most aggressive thyroid cancer, because the combination has produced multi-year survivors in early series. | Early clinical | |
Brain metastases included by default in every solid-tumour trial Up to a fifth of people with advanced solid tumours have cancer in the brain and are usually barred from trials. Letting in those whose brain disease is treate… | Early clinical | |
BTK degraders to pre-empt resistance in frontline CLL If destroying BTK works when every inhibitor has failed, using it first might stop resistance from ever emerging. | Early clinical | |
Cardiometabolic screening and treatment for survivors on long-term hormone therapy Hormone-blocking treatments for prostate and breast cancer, taken for years, raise the risk of diabetes, heart disease and bone fractures. Survivors on these d… | Early clinical | |
CDK4-selective inhibitors as the new first-line backbone If a CDK4-only drug matches CDK4/6 inhibitors on efficacy with less neutropenia, continuous dosing and better adherence could translate into longer control. | Early clinical | |
Clearing the JAK2 clone in polycythaemia vera: interferon plus mutant-selective inhibitors as a route to treatment-free remission Today's PV drugs control blood counts but leave the mutant cells in place. Interferon is the one treatment that shrinks the clone, and the first JAK2 V617F-sel… | Early clinical | |
Covalent chemistry for the RAS mutations that still have no drug One RAS mutation can now be drugged because it offers a reactive handle. Most RAS mutations do not, so new chemistry is needed to grab other amino acids. | Early clinical | |
ctDNA-guided switching among FGFR inhibitors Track FGFR2 resistance mutations in blood and switch to the next-generation inhibitor that still covers them, before the scan shows progression. | Early clinical | |
Dose adjustments driven by patients' own symptom reports, tested against clinician judgement Patients report symptoms on their phone each week; a set of rules turns severe or worsening symptoms into a dose hold or reduction before the next clinic visit… | Early clinical | |
Fund trials that test shorter courses of the most expensive adjuvant drugs The PERSEPHONE trial showed six months of trastuzumab after surgery is as good as twelve, halving the drug cost; no company will run such trials, so public fun… | Early clinical | |
Group trials by broken mechanism, not by organ or single mutation Rare cancers often share a broken cellular machine even when they arise in different organs. Grouping patients by that shared fault makes trials possible. | Early clinical | |
Hormone tablets instead of surgery for small breast cancers in the frail over-80s Frail women over 80 with small hormone-sensitive breast cancers may do as well with a daily tablet as with surgery. A trial would define who can safely avoid t… | Early clinical | |
Keep them asleep: dormancy maintenance as adjuvant therapy Instead of trying to kill every hidden cancer cell after surgery, keep them dormant for life with low-toxicity drugs, the way extended hormone therapy already… | Early clinical |
From 1 record:Small-molecule API synthesis
API synthesis, tablets and sterile vials. The 2023 cisplatin and carboplatin shortage and the BCG shortage are the worked examples.
Small-molecule API synthesisOral solid dose manufacturing (tablets and capsules)Generic sterile injectables (the 2023 platinum shortage)Sterile fill-finish and lyophilisationBCG manufacturing and the bladder cancer BCG shortageGeneric oncology drug supply and shortage mitigationGMP, inspections, Form 483s and warning letters
CompaniesIntas Pharmaceuticals (Accord Healthcare)Teva PharmaceuticalsFresenius KabiPfizer (incl. Seagen)Hikma PharmaceuticalsAmneal PharmaceuticalsSun Pharmaceutical IndustriesDr. Reddy's LaboratoriesCiplaSandozViatrisCivica RxMerck & Co. (MSD)
The manufacturing map draws every site and the seven supply chains.
Before a tablet or a vial exists, the active drug itself has to be made: many chemical steps in reactors, or extraction from a plant, at a handful of factories most patients never hear of. When one o…
The medicines are the ones the open drug engine files under small-molecule inhibitors, whether it placed them on its grid or listed them as unresolved. The technology records are listed by hand (src/lib/modular-formats.ts) and each carries a pill back here. Everything else follows the graph's links from those two sets: approvals, cancers and toxicity from the medicine records; companies, trials, papers and ideas from the records that name a medicine or technology; roadmap steps from their refs; resistance from the atlas; manufacturing from the site and supply chain records.
Nothing here is written for the hub. Where the corpus holds no record for a section, the section says so rather than filling the gap, and the counts are counts of records in OnCo, not of the world. The JSON companion carries every section with the record ids behind it. Not medical advice.